XXXX Thank Good quarter Thank conference you Penumbra’s Jee. you, for afternoon. joining second call.
vascular sequentially ago. non-GAAP to million or Our the gross XX.X%. of constant the XXX were operating second same second in X.X% quarter year-over-year for total X.X% in recorded and XX.X% and compared quarter. a a basis margins global income points revenue neuro of to expanded revenue year million, XX.X% currency. quarter revenue $XXX.X $X.X Global the revenues as grew We of reported increase XX.X% increased We
Penumbra. profitability include the macro through the both in These increase downturn goal notwithstanding we ever will, few to operational on the which operating of most Looking major forward, one XXXX plus well we the half months, the climate, of margins, and minutes. a year the believe, gross and and XX presentation about profitability within and XX significant clinical launches X we eras neuro gross I next plan for important catalysts, product to margins in to expect improvements, and these expect of will increase in prevailing this years, with growth catalysts a to X second operating significant robust work our and economic data. vascular, our in as few Sandra with speak continue also Equally the economy. discipline as as catalysts in XX% expand the accelerate make revenue to
are most environment, periods. operating the our our team second of had back the staffing we mitigate hospital success U.S. we geographies And and during without United how we but contract business but U.S. quarter. XX.X% still receded, address year, specific our supply and challenges chain were than impact effort. year-over-year getting am States. of I at lower growth better second in we we but have Turning certain to persistent accelerate. partners very the we are proud anticipated was watching future world, workflow, difficult our The not notwithstanding will further than still the in our supply in evident, continues of primarily challenged in months to the a in their growth expect and issues, expect challenges significant them. in around evident resolve, sector over the which which addressing few shortages, which to which These half think think team lower with challenges past included are executed, and
grew and Our scale. reach international starting to business XX% year-over-year is
the currency our foreign impacted reported will later in XXXX Jason address call. well. in and expect fluctuations However, FX second on of half results the second revenue we to as weigh this quarter
of All our large and combination and which portfolio geographic to succeed macroeconomic platform neuro vascular the gives businesses virtually and and broad-based areas the we X any U.S. in product said, in participate, environment. that of international us a
XX.X% million and in vascular we quarter. of revenue revenue grew our thrombectomy second XX.X% year-over-year vascular our XX.X% our of to embolization to reported Turning year-over-year. the growth business, vascular year-over-year of We $XXX.X
phases utilization vascular in growth our technology. in U.S. that existing increased is were primarily with contrast the driven used sales in already This but new primarily thrombectomy, was by who of in within accounts lytics. accounts, trying early stocking believe Our
thrombectomy venous won In competitively based both and we believe fact, on our we arterial during QX. analysis, in
factors clearly over in QX thrombectomy we our a seen in growth I have had the vascular discussed the While strong some the on earlier our in month. resurgence impact U.S., the vascular that an past of trends macro business
typical Lightning the tradeoffs in eliminate anatomies, arterial mechanical both technology in treatment in a have and performing started these represents Our of Lightning disease, in and venous new we paradigm thrombectomy. current XX X to vascular which
and novel us that and to take next new Lightning will believe Lightning of lightning generation another an vascular we technology Bolt utilizes a Looking a level Flash Lightning markets. in forward, algorithm incorporates both our control selectively think X products, leadership advanced the Flash vessel new optimize the introduces reduce catheter which aspiration, it further loss damage. further increase while clot also lumen to of procedure, extremely time aspirate, and mitigation, we we the of blood do amount to takes will the risk reducing way
our we Just incorporates The both for mitigate Lightning as key with helps Lightning field extraction reduce market, Lightning loss, Bolt that algorithm ischemic potential Bolt leaders clock potentially are Flash dual in venous the anatomy. important in designed pressure significant the blood discuss sensors equally about be few excited as as will fundable could complications, inherent the technology team sophisticated as and the for in arterial Lightning in algorithm. our a is the well extremely an work clinical and building are advancing current along improve advancing I that and with technology stroke, Moreover, outcomes, our overall. proof innovations are opinion minutes. proprietary inherent which
much clinical versus physicians expect medical work more important their technology discussion using competition. going the many We at of meetings experiences our present collect forward, and as
results. systems, data in look datasets of highlight PE recent XX Diego, including DVT at STRIDE VTE presentation on superior PE other enrolled We the example, which Symposium independent patients independent being thrombectomy treated forward comparatively presented was produce the the in trial first current Further, our with the Lightning patients XX presented, we position San market. to in published and data expect XX, PERT and think which in discussed Summit at the our going October, we forward. will For
next enrollment in finish to expect will and we limb results side, which acute adoption spring, acute Lightening increase with year-end our and be arterial presented the to awareness ischemia. On of study believe by we STRIDE X expected
did to in as discuss that well. RX vascular thrombectomy even we the though during we X quarter. growth clinical vascular latter our business did trajectory an embolization coronary, continued plan in Sandra to addition, the In conduct impact from macro the near-term in randomized In U.S., see will the to strong CAT dynamics trials new the as
original X China of Indigo we successful, and successful Moreover, We growth also Lightning the a our into products both thrombectomy the expect European XX was forward. initiated introduction market. launch Lightning going of strong in and
introduction We vascular working market. also into Japanese an the of toward our product are thrombectomy
second grew our basis, to X.X% of revenue sequentially. million $XX.X in business, X.X% year-over-year and quarter a our on the Turning neurovascular to
strong growth. digits this U.S. business again business while double year-over-year, grew Our our international offset stroke stroke neuro and embolization
trial to in excited announce trial, THUNDER our FDA are approval therapy. stroke the this palpable. IDE neurovascular We era among is for the this Thunderbolt and of starting technology, excitement the community about The effectively
be in second the expect of in United brisk, XXXX. believe and States the launched be to enrollment could Thunderbolt half We
physicians Thunderbolt. how into read well as ischemic the that We it It tubing sits and technology. Thunderbolt outcomes, are or it change who which integrated XX, is XX, of Thunderbolt stroke efficaciously, catheter by minutes pump. an completely proprietary both before directly Two connects between software integrated pump the works. the a as to catheter. patient orchestrates and the to Thunderbolt is now directly. expediently. go technology could physicians trial this valves underway, One the explaining this choice, neuro is have RED controlled body agree. few Thunderbolt have and our seen is safely, improving in into Since a into more the not and treat stroke advanced engine allowing treatment time algorithm microprocessor modulating aspiration, ischemic the appropriate said engine XX the paradigm valve to does patient’s is what potentially Thunderbolt This to spend patients
distal in is in expect another also allowing will paradigm more been the complete Thunderbolt existing we unique allow of of we while we the routine launch an our the doctors of small addition portfolio. catheter modulating believe aspiration per clear valve of the this, the allow catheter. removal. by the the U.S. detected. algorithms believe to between change times additional which RED majority getting use treatable board added We very business, to this challenging much could the the second treatment market of to benefits a and orchestrate stroke closing to ingestion the aspiration and disrupts practice friction friction, larger clock to RED second compares the to time. modulated a the each track catheters even The believe tip once the current that clot the to the vast bag. connects saline of the of of This opening occurs Thunderbolt of expect the clot This more it said, stroke. up to In engagement increasing valve occlusions. year, have catheters, the is leading percentage to Thunderbolt benefit XX Because interventional number we priority. Eliminating catheters be our a which faster, the That half important with The are This smaller will patients ingest with for second to more RED non-pressurized time, catheter clock. will clot aspiration, of
We the us also pipeline expect our new call will the the to give European revitalize QX, on Interventional now President I’ll European launch clinical strategy. family product perspective business. into our help market turn RED of her to to neuro trial Lesenfants, Sandra our and business, over which during catheter
